Ipsen Biopharmaceuticals, Inc.
Ipsen Biopharmaceuticals, Inc., a prominent player in the biopharmaceutical industry, is headquartered in the United States and operates extensively across North America and Europe. Founded in 1929, Ipsen has established itself as a leader in the development of innovative therapies, particularly in oncology, neuroscience, and rare diseases. The company is renowned for its core products, including Somatuline® and Dysport®, which are distinguished by their unique formulations and targeted delivery mechanisms. Ipsen's commitment to research and development has led to significant milestones, including the expansion of its product portfolio and strategic partnerships that enhance its market position. With a focus on patient-centric solutions, Ipsen continues to achieve notable recognition within the biopharmaceutical sector, driving advancements that improve patient outcomes globally.
DitchCarbon Score
How does Ipsen Biopharmaceuticals, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Ipsen Biopharmaceuticals, Inc.'s score of 46 is higher than 61% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Ipsen Biopharmaceuticals, Inc.'s reported carbon emissions
Ipsen Biopharmaceuticals, Inc., headquartered in the US, currently does not have publicly available data regarding its carbon emissions or specific climate commitments. As such, there are no reported figures for emissions in kg CO2e, nor are there defined reduction targets or initiatives outlined in their sustainability strategy. In the absence of specific emissions data, it is important to note that many companies in the biopharmaceutical sector are increasingly focusing on sustainability and climate action. This often includes commitments to reduce greenhouse gas emissions across all scopes—Scope 1 (direct emissions), Scope 2 (indirect emissions from energy), and Scope 3 (indirect emissions from the supply chain). Ipsen's approach to climate commitments may align with industry trends, which typically involve setting science-based targets and participating in global climate initiatives. However, without specific information, it is unclear what Ipsen's current strategies or future goals may be in relation to carbon emissions and climate action.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Ipsen Biopharmaceuticals, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
